Charting the Grand Blueprint · Pioneering the Future | Warm Congratulations on the Grand Opening of Vickor QiYuan (Wuxi) Medical Technology Co., Ltd.!
Time:
2025-05-08
Wuxi, China – May 8, 2025 – Vickor QiYuan (Wuxi) Medical Technology Co., Ltd. celebrated its grand opening alongside the mid-term symposium for a National Key R&D Program project in Liangxi District, Wuxi. Under the theme "Charting the Blueprint · Pioneering the Future," the event marked a significant milestone in Vekcare Medical's strategic expansion within the cardiovascular innovation sector. Distinguished attendees included leaders from Liangxi District government, renowned medical experts, industry partners, leading investment firms, and corporate executives.
Attending Dignitaries Included:
Mr. Xin Le, Deputy District Head of Liangxi District; officials from the District Commerce Bureau, Health Commission, Market Supervision Administration, and Shanbei Subdistrict Office; Prof. Wang Guixue (Former Dean, Bioengineering College, Chongqing University); Prof. Cao Chengbo (Director, Light Industry Textile & Medical Materials Institute, Shandong University); Prof. Hu Kanghong (Director, Sino-German Biomedical Center, Hubei University); Prof. Dong Xufeng (Vice Dean, School of Materials Science & Engineering, Dalian University of Technology); Prof. Zhuang Xijing (Vice President, Dalian Municipal Central Hospital); Prof. Dai Xiaozhen (Dean, School of Biological Science and Technology, Chengdu Medical College); Prof. Zhang Xing (Chinese Academy of Sciences, Institute of Metal Research); Prof. Bai Yu (School of Management, Wuhan University of Technology); Prof. Wang Yin (Party Committee Secretary, Macrovascular Surgery Department, Wuhan Union Hospital); Prof. Ouyang Chenxi (Fuwai Hospital, Chinese Academy of Medical Sciences); Prof. Hong Feng (School of Chemistry, Chemical Engineering & Biotechnology, Donghua University); Prof. Zhang Quanchao (Institute for Advanced Materials, East China Jiaotong University); Prof. Li Hanluo (Biomedicine Research Institute, Hubei University of Technology); Prof. Wang Hao (School of Materials Science & Engineering, Wuhan University of Technology); Vickor Medical Founders Mr. Shang Xiaoke, Ms. Wang Xueli, Mr. Chen Song; Mr. Zhou Baolei, Deputy General Manager; Mr. Zhang Juncai, Partner, Bohua Capital; Ms. Zhu Aojia, Investment Director, Bohua Capital; Ms. Shen Qin, Partner, Shengyu Investment; Mr. Li Zhe, Partner, Biling Capital; alongside other experts and partners.
01 A New Chapter | Innovation-Driven, Shaping the Future of Cardiac Care
The opening ceremony commenced at 8:00 AM to enthusiastic applause. Mr. Chen Song, Co-founder of Vickor Medical and General Manager of Vickor QiYuan; Prof. Cao Chengbo, Director of the Light Industry Textile & Medical Materials Institute at Shandong University; and Mr. Zhang Juncai, Partner at Bohua Capital, delivered keynote addresses outlining the company’s vision.
Mr. Chen Song, GM, Vickor QiYuan:
"For six years, Vickor Medical has upheld its mission of 'Creating Possibilities for Life,' successfully developing innovative products including PFO Occluders, Atrial Shunt Devices, and Transcatheter Aortic Valve Replacement systems. Today, with the strong support of the Liangxi District government, Vickor QiYuan sets sail. Serving as our innovation engine in the Yangtze River Delta, we will leverage Wuxi’s exceptional R&D ecosystem and efficient, pragmatic business policies to accelerate the translation of innovations and propel more 'Created in China' solutions onto the global stage!"
Prof. Cao Chengbo:
"Vickor’s technological expertise in cardiovascular interventional devices is truly impressive. The establishment of Vickor QiYuan signifies a new phase in industry-academia-research collaboration. We anticipate breakthroughs in biocompatible materials, medical-engineering co-innovation, and technology transfer. Building on Wuxi’s robust biomedical ecosystem, Vickor QiYuan will drive technological advancements in interventional devices, delivering superior medical solutions for patients."
Mr. Zhang Juncai, Bohua Capital:
"Vekcare Medical’s unique 'Medical-Engineering Integration' ecosystem brings together top clinical experts, materials scientists, and seasoned engineers, forging a competitive clinically-driven product development system. As the lead investor in Series C, Bohua Capital fully supports Vickor’s strategic move to establish an active device R&D center in Wuxi. We remain committed to backing the company’s international expansion, facilitating the industrialization of innovative technologies, and achieving its global strategic footprint."
02 Leading the Wave | Ribbon-Cutting and Facility Tour
Following the speeches, distinguished guests jointly cut the ribbon, officially inaugurating Vickor QiYuan amidst resounding applause.
Accompanied by GM Chen Song and the executive team, guests toured the state-of-the-art exhibition hall and core R&D center. Innovations on display, such as the intelligent heart failure monitoring system and the miniature interventional cardiac assist pump, vividly demonstrated Vickor Medical’s integrated "Monitoring-Treatment-Rehabilitation" full-cycle solutions. Their significant clinical value and vast industrialization potential garnered unanimous praise from attending experts.
03 Forging Breakthroughs | Academia-Industry-Research-Medicine Synergy
Experts from leading universities and research institutions engaged in in-depth discussions on the mid-term progress of the National Key R&D Program project: "Key Technologies for Functionalized Vascular/Heart Valve Materials and Prosthesis Construction." The synergy between clinical data and engineering insights provided fresh perspectives for tackling project challenges, ensuring the smooth progression of the next phase.
The launch of Vickor QiYuan today marks not only a new chapter for Vickor Medical but also a powerful declaration of China’s independent innovation in high-end medical devices. Moving forward, Vickor will harness Wuxi as its innovation engine, guided by clinical value and driven by the mission to enhance patient quality of life, navigating confidently toward new horizons in cardiovascular technology.
About Vickor QiYuan
Vickor QiYuan (Wuxi) Medical Technology Co., Ltd., a wholly-owned subsidiary of Wuhan Vekcare Medical, is headquartered in Liangxi District, Wuxi. The company specializes in the R&D and industrialization of active cardiovascular implantable medical devices. Centered on "Monitoring-Treatment-Management" full-cycle solutions, Vickor QiYuan pioneers advanced products including:The world’s first implantable heart failure monitoring system with AI-powered dynamic early-warning algorithms.Miniature interventional cardiac assist pumps (Filling critical domestic technology gaps)
Leveraging Wuhan Vickor Medical’s clinical expertise in passive interventional devices, Vickor QiYuan synergistically advances dual-track ("Active + Passive") R&D, optimizing device-body compatibility to accelerate product development. By integrating the Yangtze River Delta’s biomedical resources, the company builds a comprehensive "Basic Research → Clinical Translation → Global Commercialization" platform, shortening R&D cycles through talent and supply chain collaboration. Vickor QiYuan will utilize Hong Kong as an international springboard, targeting both European/American and Belt and Road Initiative markets, propelling China’s cardiovascular devices from import substitution to global innovation.
©2023 Wuhan Vickor Medical Technology Co., Ltd.
This site already supports IPV6 access | SEO | Business License